Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
2019.11.25
Active substance: methotrexate
The Federal Institute for Drugs and Medical Devices (BfArM) is implementing the corresponding implementing decision of the European Commission C(2019) 7680 final of 21 October 2019 by decision of 20 November 2019.
New measures to avoid potentially fatal dosage errors with methotrexate in inflammatory diseases
EMA has recommended new measures to prevent serious and potentially fatal dosing errors in methotrexate for the treatment of inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
PRAC recommends new measures to avoid dosing errors with methotrexate
The Federal Institute for Drugs and Medical Devices (BfArM) issues information on the initiation of a safety review by the European Medicines Agency (EMA) to review the risk of dosing errors with methotrexate.
For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):